On May 15, 2025, HC Wainwright & Co. reaffirmed their 'Buy' rating for Adverum Biotechnologies (ADVM, Financial). The company's current analyst Matthew Caufield maintained their price target at $30.00 USD.
The price target for Adverum Biotechnologies (ADVM, Financial) remains unchanged from its prior target, with no percentage change noted in this adjustment. The consistent rating of 'Buy' suggests continued positive outlook from the analyst regarding the stock's future performance.
Investors watching Adverum Biotechnologies (ADVM, Financial) may find this reiteration significant as it reflects confidence in the company's prospects from a prominent financial analyst. The maintained price target at $30.00 USD underscores the expected valuation according to HC Wainwright & Co.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Adverum Biotechnologies Inc (ADVM, Financial) is $21.25 with a high estimate of $33.00 and a low estimate of $4.00. The average target implies an upside of 931.55% from the current price of $2.06. More detailed estimate data can be found on the Adverum Biotechnologies Inc (ADVM) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Adverum Biotechnologies Inc's (ADVM, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
